Top Markets
#1 Trillions Trillions +5,127.61%
#2 Black Phoenix Black Phoenix +4,074.95%
#3 DeFiChain DeFiChain +1,700.88%
#4 Siren Siren +198.16%
#5 Bedrock Bedrock +120.41%
#6 KONET KONET +64.17%
#7 inSure DeFi inSure DeFi +60.27%
#8 Aria.AI Aria.AI +59.06%
#9 Banana For Scale Banana For Scale +46.83%
#10 TRIA TRIA +26.51%
Coin of the day
Trillions Trillions
Settings
Language
ENGLISH
Currency
USD
Theme
Ovoca Bio plc Ovoca Bio plc

Ovoca Bio plc

OVB
Rank in Stocks #99999
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the... Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.
Share Price
$0.09933121
Market Cap
$29.15K
Change (1 day)
0.57%
Change (1 year)
449.49%
Country
IE
Trade Ovoca Bio plc (OVB)

Category

Healthcare
Earnings for Ovoca Bio plc (OVB)
Earnings in Jun 2024 TTM: $-5.54M
According to Ovoca Bio plc latest financial reports the company's current earnings are $-5.54M. In 2023 the company made an earning of $-5.64M, an increase over its 2022 earnings that were of $-6.02M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Ovoca Bio plc from 2001 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-5.54M 177,402.36%
2024 $-3.12K -99.94%
2023 $-5.64M -6.27%
2022 $-6.02M 0.89%
2021 $-5.97M 111.35%
2020 $-2.82M 32.29%
2019 $-2.13M -6.96%
2018 $-2.29M 401.73%
2017 $-457.16K -54.69%
2016 $-1.01M -58.18%
2015 $-2.41M -69.99%
2014 $-8.04M -60.54%
2013 $-20.37M 592.33%
2012 $-2.94M -153.33%
2011 $5.52M 340.98%
2010 $1.25M -87.44%
2009 $9.96M -683.08%
2008 $-1.71M 36.71%
2007 $-1.25M -81.83%
2006 $-6.88M 549.04%
2005 $-1.06M 285.00%
2004 $-275.29K 10.93%
2003 $-248.17K 96.02%
2002 $-126.60K -32.76%
2001 $-188.29K 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -369,289.88%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -83,895.77%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -94,498.38%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -38,678.95%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -26,287.63%
NL